ArticleFuture oncology (London, England)2025

STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC.

Nabil F Saba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.